Triamterene 50mg capsules
Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension.
Safety information for pregnancy and breastfeeding
Pregnancy
Breastfeeding
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Triamterene
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Triamterene
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Triamterene
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
6 branded products available
WHO defined daily dose (DDD)
100 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · 1962–2026
Showing the 50 most relevant studies, sorted by most relevant.
Mohammadreza Taban-sadeghi, E. Khani, Kimia Khezripour, et al.
The Journal of Clinical Pharmacology, 2023
- Diuretics
- Heart Failure
- Potassium
Laurent Favre, PHILIPPE GLASSON, MICHEL B. VALLOTTON
Annals of Internal Medicine, 1982
- Creatinine
- Diuretics
- Drug Interactions
Gholamhossein Sodeifian, Chandrasekhar Garlapati, Seyed Mojtaba Hazaveie, et al.
Journal of Chemical & Engineering Data, 2020
Fulin Mao, Weizhong Shi, Hongkun Zhao, et al.
The Journal of Chemical Thermodynamics, 2024
Heidi R. Abd El-Hadi, M. Eissa, H. Zaazaa, et al.
BMC Chemistry, 2023
Lewis W. Dittert, Takeru Higuchi, Davis R. Reese
Journal of Pharmaceutical Sciences, 1964
- Chemistry, Pharmaceutical
- Pharmacy
- Research
Bruce Ettinger
JAMA: The Journal of the American Medical Association, 1980
- Calcium Oxalate
- Chromatography, Thin Layer
- Kidney Calculi
K. To, K. Cheung, W. Cho
Journal of Cancer Research and Clinical Oncology, 2023
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Antineoplastic Agents
Ahmed A. Khorshed, Fatma M. Abdelnaeem, Mohamed Oraby, et al.
Microchemical Journal, 2025
Mina Delkhani, M. Khajenoori, A. H. Asl
Arabian Journal for Science and Engineering, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
103 found
Half-life
1.5 to 2 hours
Mechanism
Triamterene inhibits the epithelial sodium channels (ENaC) located on the lumena…
Food interactions
1 warning
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
2 to 4 hours
Half-life
1.5 to 2 hours
[L6193]
…
Protein binding
67%
[L6166]
Volume of distribution
1.49 L/kg
Metabolism
Elimination
50%
[L6193]
…
Clearance
4.5 l
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.[L6163] Currently, triamterene is used in the treatment of edema associated with various conditions as monotherapy and is approved for use with other diuretics to enhance diuretic and potassium-sparing effects.[L6166] It is also found in a combination product with hydrochlorothiazide that is used for the management of hypertension or treatment of edema in patients who develop hypokalemia on hydrochlorothiazide alone.
[L6166]
Triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy, and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be risked.
[L6169]
Triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazides.[T28]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1366 interactions
Dialysis may be somewhat effective in case of an overdosage.
[L6166]
In a carciongenicity study in male and female mice administered with triamterene at the highst dosage level, there was an increased incidence of hepatocellular neoplasia, primarily adenomas. However, this was not a dose-dependent phenomenon and there was no statistically significant difference from control incidence at any dose level. In bacterial assays, there was no demonstrated mutagenic potential of triamterene.
In in vitro assay using Chinese hamster ovary (CHO) cells with or without metabolic activation, there were no chromosomal aberrations. Studies evaluating the effects of triamterene on reproductive system or fertility have not been conducted. It is advised that the use of triamterene is avoided during pregnancy.
As triamterene has been detected in human breast milk, triamterene should be used when nursing is ceased.
[L6166]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L6166]
In a pharmacokinetic study, the oral bioavailability of triamterene was determined to be 52%.
[A178012]
Following administration of a single oral dose to fasted healthy male volunteers, the mean AUC of triamterene was about 148.7 ng*hr/mL [L6169] and the mean peak plasma concentrations (Cmax) were 46.4 ng/mL reached at 1.1 hour after administration.
[L6169]
In a limited study, administration of triamterene in combination with hydrochlorothiazide resulted in an increased bioavailability of triamterene by about 67% and a delay of up to 2 hours in the absorption of the drug.
[L6169]
It is advised that triamterene is administered after meals; in a limited study, combination use of triamterene and hydrochlorothiazide with the consumption of a high-fat meal resulted in an increase in the mean bioavailability and peak serum concentrations of triamterene and its active sulfate metabolite, as well as a delay of up to 2 hours in the absorption of the active constituents.
[L6169]
[L6193]
In a pharmacokinetic study involving healthy volunteers, the terminal half-lives for triamterene and 4′-hydroxytriamterene sulfate were 255 ± 42 and 188 ± 70 minutes, respectively, after intravenous infusion of the parent drug.
[A577][L6163]
[L6166]
[A577]
Triamterene was found to cross the placental barrier and appear in the cord blood of animals.
[L6166]
[A39120][L6163]
Both the plasma and urine levels of this metabolite greatly exceed triamterene levels [L6166] while the renal clearance of the sulfate conjugate was les than that of triamterene; this low renal clearance of the sulfate conjugate as compared with triamterene may be explained by the low unbound fraction of the metabolite in plasma.
[A178057]
[L6193]
Upon oral ingestion, somewhat less than 50% of the oral dose reaches the urine.
[L6166]
About 20% of an oral dose appears unchanged in the urine, 70% as the sulphate ester of hydroxytriamterene and 10% as free hydroxytriamterene and triamterene glucuronide.
[L6193]
[A577]
Proteins and enzymes this drug interacts with in the body
PMID:30251954 PMID:32729833 PMID:7550319 PMID:7762608 PMID:9792722
ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically .
PMID:24124190
It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys .
PMID:12107247 PMID:7550319 PMID:8640238
Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance PMID:18507830 PMID:19017867 PMID:24124190
PMID:30251954 PMID:32729833 PMID:8023962 PMID:8278374 PMID:9792722
ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically .
PMID:24124190 PMID:28710092 PMID:8278374
It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys .
PMID:12107247
Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance PMID:24124190 PMID:28710092
PMID:30251954 PMID:32729833 PMID:7762608 PMID:9792722
ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically .
PMID:24124190
It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys .
PMID:12107247
Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance PMID:24124190
PMID:16423824 PMID:19520916 PMID:22505667
ENaC functions in epithelial tissues, where it facilitates the electrodiffusion of sodium ions from the extracellular fluid through the apical membrane of cells, with water following osmotically, regulating sodium balance and fluid homeostasis .
PMID:16423824 PMID:19520916 PMID:7499195
This subunit could also function independently as a sodium channel or assemble into other tissue-specific heterotrimeric sodium channels PMID:7499195
Enzymes involved in drug metabolism — important for understanding drug interactions
Involved compounds
ATC C03DB02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Triamterene
Additional database identifiers
Drugs Product Database (DPD)
10190
ChemSpider
5345
BindingDB
6644
PDB
DX2
Guide to Pharmacology
4329
ZINC
ZINC000000120286
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10602
GenAtlas
SCNN1G
GeneCards
SCNN1G
GenBank Gene Database
X87160
GenBank Protein Database
1004273
Guide to Pharmacology
741
UniProt Accession
SCNNG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10599
GenAtlas
SCNN1A
GeneCards
SCNN1A
GenBank Gene Database
X76180
GenBank Protein Database
452650
Guide to Pharmacology
738
UniProt Accession
SCNNA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10600
GenAtlas
SCNN1B
GeneCards
SCNN1B
GenBank Gene Database
X87159
GenBank Protein Database
1004271
Guide to Pharmacology
739
UniProt Accession
SCNNB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10601
GenAtlas
SCNN1D
GeneCards
SCNN1D
GenBank Gene Database
U38254
GenBank Protein Database
1066457
UniProt Accession
SCNND_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72